Neuropathy clinical trials at UCSF

6 in progress, 1 open to eligible people

Neuropathy is damage to nerves that changes how the body senses touch or moves. UCSF is evaluating a one-time surgical gene therapy given to one or both ears to assess safety. UCSF is following people after the procedure and checking two dose levels for side effects.

Showing trials for

  • Gene Therapy Trial for Otoferlin Gene-mediated Hearing Loss

    open to all eligible people

    Part A of this trial evaluated the safety and tolerability of a single surgical administration procedure in one or both ear(s) with one of two dose levels of AAVAnc80-hOTOF (LY888891) and evaluated the Akouos Delivery Device, together with the Precision Delivery Mechanism (as applicable), to safely achieve the intended product performance. Part B of the trial is an open-label, global expansion phase to confirm the efficacy and safety of one dose level of AAVAnc80-hOTOF administered in one or both ear(s). Part B will also evaluate the Intracochlear Delivery System (IDS), which consists of the Akouos Delivery Device, the Precision Delivery Mechanism, and an off-the-shelf syringe. Part C is a region-specific expansion phase. Part C participants will receive the same dose level of AAVAnc80-hOTOF as participants in Part B, in one or both ear(s) utilizing the IDS. Part D is a sequential administration phase that allows participants who received AAVAnc80-hOTOF previously in a single ear to receive AAVAnc80-hOTOF administration in the other ear utilizing the IDS.

    San Francisco, California and other locations

  • Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer

    Sorry, in progress, not accepting new patients

    This phase II/III trial studies the best dose of duloxetine and how well it works in preventing pain, tingling, and numbness (peripheral neuropathy) caused by treatment with oxaliplatin in patients with stage II-III colorectal cancer. Duloxetine increases the amount of certain chemicals in the brain that help relieve depression and pain. Giving duloxetine in patients undergoing treatment with oxaliplatin for colorectal cancer may help prevent peripheral neuropathy.

    San Francisco, California and other locations

  • Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy

    Sorry, in progress, not accepting new patients

    The main purpose of this study is to compare empasiprubart and IVIg in adult patients with MMN. The study consists of a double-blinded part A (empasiprubart, IVIg) and an open-label part B (empasiprubart). The maximum study duration for participants is up to 49 months. More information can be found here: https://clinicaltrials.argenx.com/empassion

    San Francisco, California and other locations

  • Laryngopharyngeal Sensation: Cancer Survivor Cohort

    Sorry, not yet accepting patients

    A previous study completed in 2022 (NCT05158179) was conducted using cohorts of healthy controls, and adults with general laryngopharyngeal disorders. This study will expand on the previous research to include a separate cohort of adults being seen in clinic for an existing laryngopharyngeal disorder resulting from previous radiation or other cancer treatments.

    San Francisco, California

  • Long-Chain Fatty Acid Oxidation Disorders In-Clinic Disease Monitoring Program

    Sorry, in progress, not accepting new patients

    The primary objective of this study is to assess the long-term safety, including pregnancy, infant, and lactation outcomes, of patients with LC-FAOD who are enrolled in the DMP.

    San Francisco, California and other locations

  • Longitudinal Study in Adults With Multifocal Motor Neuropathy

    Sorry, in progress, not accepting new patients

    This prospective longitudinal study will follow participants with Multifocal Motor Neuropathy over time and collect data on their clinical outcomes, quality of life, and use of health care resources. Participants will follow their regular visit schedule with their treating physician, except for an optional second visit occurring 7 to 14 days after the start of the study to collect biomarker data. No IMP will be administered.

    San Francisco, California and other locations

Our lead scientists for Neuropathy research studies include .

Last updated: